{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T13:56:46Z","timestamp":1781704606234,"version":"3.54.5"},"reference-count":17,"publisher":"Norwegian Medical Association","issue":"15","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tidsskr Nor Legeforen","Tidsskriftet"],"DOI":"10.4045\/tidsskr.18.0093","type":"journal-article","created":{"date-parts":[[2018,10,2]],"date-time":"2018-10-02T05:24:04Z","timestamp":1538457844000},"source":"Crossref","is-referenced-by-count":1,"title":["Overgangen fra digitoksin til digoksin i \u00e5rene 2011\u201313"],"prefix":"10.4045","volume":"138","author":[{"given":"Knut","family":"Lien","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7902-9014","authenticated-orcid":false,"given":"Olav","family":"Spigset","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas Austgulen","family":"Westin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Sl\u00f8rdal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2479","published-online":{"date-parts":[[2018,10,1]]},"reference":[{"key":"ref=1","doi-asserted-by":"crossref","unstructured":"Ziff\u00a0OJ, Kotecha\u00a0D. Digoxin: The good and the bad. Trends Cardiovasc Med 2016; 26: 585\u201395. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=27156593&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2Fj.tcm.2016.03.011","DOI":"10.1016\/j.tcm.2016.03.011"},{"key":"ref=2","doi-asserted-by":"crossref","unstructured":"Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336: 525\u201333. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9036306&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1056%2FNEJM199702203360801","DOI":"10.1056\/NEJM199702203360801"},{"key":"ref=3","doi-asserted-by":"crossref","unstructured":"Rathore\u00a0SS, Curtis\u00a0JP, Wang\u00a0Y et al. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 2003; 289: 871\u20138. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12588271&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1001%2Fjama.289.7.871","DOI":"10.1001\/jama.289.7.871"},{"key":"ref=4","doi-asserted-by":"crossref","unstructured":"Lely\u00a0AH, van Enter\u00a0CH. Large-scale digitoxin intoxication. BMJ 1970; 3: 737\u201340. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=5273245&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1136%2Fbmj.3.5725.737","DOI":"10.1136\/bmj.3.5725.737"},{"key":"ref=5","unstructured":"Statens legemiddelverk. Overgang fra digitoksin til digoksin hos voksne. https:\/\/legemiddelverket.no\/nyheter\/overgang-fra-digitoksin-til-digoksin-hos-voksne (20.1.2018)."},{"key":"ref=6","doi-asserted-by":"crossref","unstructured":"Haga\u00a0C, Opdal\u00a0MS, Tuv\u00a0SS et al. Legemiddelsikkerhet ved bytte av digitalispreparat i Norge. Tidsskr Nor Legeforen 2016; 136: 1714\u20138. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=27830905&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.4045%2Ftidsskr.15.0161","DOI":"10.4045\/tidsskr.15.0161"},{"key":"ref=7","doi-asserted-by":"crossref","unstructured":"Schj\u00f8tt\u00a0J, Torgauten\u00a0HM, Bj\u00e5nes\u00a0TK. Shortage of digitoxin and switching to digoxin in Norway: a retrospective study of blood samples submitted to a clinical pharmacology laboratory. Basic Clin Pharmacol Toxicol 2017; 121: 74\u20137. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=28235161&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1111%2Fbcpt.12770","DOI":"10.1111\/bcpt.12770"},{"key":"ref=8","unstructured":"Roche Diagnostics. Digoxin (DIG). I: Pakningsvedlegg for digoksinanalyser p\u00e5 Cobas Integra 400\/800 analyseinstrument (v11 NO). Mannheim: Roche Diagnostics GmbH, 2012: 1\u20134."},{"key":"ref=9","doi-asserted-by":"crossref","unstructured":"Smith\u00a0TW. Pharmacokinetics, bioavailability and serum levels of cardiac glycosides. J Am Coll Cardiol 1985; 5 (suppl A): 43A\u201350A. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=3921586&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2FS0735-1097(85)80462-9","DOI":"10.1016\/S0735-1097(85)80462-9"},{"key":"ref=10","unstructured":"Committee for Medicinal Products for Human Use. Guideline on the investigation of bioequivalence. London: European Medicines Agency, 2010: 15. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2010\/01\/WC500070039.pdf (20.1.2018)."},{"key":"ref=11","unstructured":"Br\u00f8rs O. Legemiddelanalyser og rusmiddelanalyser. I: Norsk legemiddelh\u00e5ndbok for helsepersonell 2004. Oslo: Foreningen for utgivelse av Norsk legemiddelh\u00e5ndbok, 2004: 1601\u20138."},{"key":"ref=12","unstructured":"Osnes J-B, Aass H. Hjerteglykosider. I: Norsk legemiddelh\u00e5ndbok for helsepersonell 2007. Oslo: Foreningen for utgivelse av Norsk legemiddelh\u00e5ndbok, 2007: 1015\u201318."},{"key":"ref=13","doi-asserted-by":"crossref","unstructured":"H\u00f8nn\u00e5s\u00a0A, Reimers\u00a0A, Spigset\u00a0O. Dosering av digitoksin i klinisk praksis. Tidsskr Nor Legeforen 2010; 130: 1334\u20136. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=20596112&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.4045%2Ftidsskr.09.1163","DOI":"10.4045\/tidsskr.09.1163"},{"key":"ref=14","unstructured":"RELIS. Overgang fra digitoksin til digoksin. https:\/\/relis.no\/Aktuelt\/Arkiv\/2012\/Overgang_fra_digitoksin_til_digoksin\/ (20.1.2018)."},{"key":"ref=15","unstructured":"Giverhaug T, Halvorsen KH. Praktiske r\u00e5d for sikrere bytte fra digitoksin til digoksin. https:\/\/relis.no\/Bivirkninger\/Nytt_om_bivirkninger\/2012\/Praktiske_rad_for_sikrere_bytte_fra_digitoksin_til_digoksin (20.1.2018)."},{"key":"ref=16","unstructured":"Westin\u00a0AA, Larsen\u00a0R-A, Espnes\u00a0KA et al. Legemiddelanalyser i Norge. Tidsskr Nor Legeforen 2012; 132: 2382\u20137. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=23160587&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.4045%2Ftidsskr.12.0383"},{"key":"ref=17","doi-asserted-by":"crossref","unstructured":"Sl\u00f8rdal\u00a0L, Eggen\u00a0AE. Digitalisering ad modum Statens legemiddelverk. Tidsskr Nor Legeforen 2016; 136: 1700. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=27830897&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.4045%2Ftidsskr.16.0810","DOI":"10.4045\/tidsskr.16.0810"}],"container-title":["Tidsskrift for Den norske legeforening"],"original-title":[],"language":"no","deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T13:17:26Z","timestamp":1781702246000},"score":1,"resource":{"primary":{"URL":"https:\/\/tidsskriftet.no\/2018\/10\/originalartikkel\/overgangen-fra-digitoksin-til-digoksin-i-arene-2011-13"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,1]]},"references-count":17,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2018,10,2]]}},"URL":"https:\/\/doi.org\/10.4045\/tidsskr.18.0093","relation":{},"ISSN":["0029-2001","0807-7096"],"issn-type":[{"value":"0029-2001","type":"print"},{"value":"0807-7096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,1]]}}}